Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 11, 2014, Pages 1905-1910

  Facciorusso, Antonio ^a   Del Prete, Valentina ^a   Antonino, Matteo ^a   Neve, Viviana ^a   Crucinio, Nicola ^a   Di Leo, Alfredo ^b   Carr, Brian I ^c   Barone, Michele ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

HCC; Iron; Recurrence; RFA; Survival

Indexed keywords

FERRITIN; TUMOR MARKER;

ADULT; AGED; ANALYSIS OF VARIANCE; BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; FEMALE; HUMAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL RATE; TIME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; FEMALE; FERRITINS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84912006393     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12618     Document Type: Article

References (19)

1. El-Serag HB. Current concepts hepatocellular carcinoma. N. Engl. J. Med. 2011; 365: 1118-1127.
2. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56: 908-943.
3. Bruix J, Sherman M. Practice guidelines committee, American association for the study of liver disease. Management of hepatocellular carcinoma. An update. Hepatology 2011; 53: 1020-1022.
4. Livraghi T, Meloni F, Di Stasi M etal. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008; 47: 82-89.
5. Pompili M, Saviano A, de Matthaeis N etal. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3cm. Results of a multicenter Italian survey. J. Hepatol. 2013; 59: 89-97.
6. Lambrecht RW, Sterling RK, Naishadham D etal. Iron levels in hepatocytes and portal tract cells predict progression and outcome of patients with advanced chronic hepatitis C. Gastroenterology 2011; 140: 1490-1500.
7. Al-Freah MAB, Kriese S, Foxton MR etal. The association of pretransplant ferritin level with waiting list and post-transplant survival. Does ferritin actually predict outcome? Transpl. Int. 2013; 26: 1070-1079.
8. Walker NM, Stuart KA, Ryan RJ etal. Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology 2010; 51: 1683-1691.
9. Kamath PS, Wiesner RH, Malinchoc M etal. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470.
10. Mazzaferro V, Sposito C, Bhoori S etal. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013; 57: 1826-1837.
11. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
12. Common Terminology Criteria for Adverse Events v4.0 NCI, NIH, DHHS. May 29, 2009 NIH publication # 09-7473. Cited January 2014. Available from http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf
13. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 2010; 30: 52-60.
14. Crowley J, LeBlanc M, Jacobson J, Salmon S. Some exploratory tools for survival analysis. In: Lyn DY, Fleming TR, eds. Proceedings of the First Seattle Symposium in Biostatistics: Survival Analysis. Lecture Notes on Statistics. New York: Springer, 1997; 199-229.
15. Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem. J. 2011; 434: 365-381.
16. Bell H, Skinningsrud A, Raknerud N, Try K. Serum ferritin and transferrin saturation in patients with chronic alcoholic and non-alcoholic liver diseases. J. Intern. Med. 1994; 236: 315-322.
17. Kowdley KV, Belt P, Wilson LA etal. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012; 55: 77-85.
18. Ba Q, Hao M, Huang H etal. Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies. Clin. Cancer Res. 2011; 17: 7625-7633.
19. Yamasaki T, Terai S, Sakaida I. Deferoxamine for advanced hepatocellular carcinoma. N. Engl. J. Med. 2011; 365: 576-578.